INVESTORS Annual Reports Financials Investor Presentations Shareholder Information Analysts Speak Events
LUPIN FOUNDATION
CAREERS Careers Overview Life at Lupin Campus Connect Learning & Development Current Openings P.L.E.D.G.E.
MEDIA Press Releases Downloadables
CONTACT US Contact Us Global Offices Partner With Us Lupin for Suppliers

Lupin has made significant strides in building a sustainable, vibrant and diverse business. One of Lupin’s differentiators has been the branded portfolio and the company is focused on re-establishing the branded business as an engine for growth.

With the acquisition of Gavis Pharmaceuticals LLC in the US, the company gained scale in the brands market. Methergine and Methylphenidate - the two new brands helped Lupin to reposition itself in the market with focus on building Women’s Health portfolio. In October 2017, the company acquired Symbiomix Therapeutics, LLC to obtain its US FDA approved brand SolosecTM.

SolosecTM, was recently launched and is the first and only approved single-dose oral treatment for Bacterial Vaginosis (BV) - the most prevalent gynecology infection in the US. The acquisition of SolosecTM significantly expands Lupin’s Women’s Health business.

Lupin’s Europe business is committed to building a robust portfolio in the specialty space within Neurology.